TScan Therapeutics Reports $175.3 Million in Cash Reserves, Funding Operations Into Second Half of 2028

TScan Therapeutics released its financial results for the first quarter of 2026 and provided a corporate update. The company highlighted its financial position and ongoing clinical programs.

Specifically, TScan Therapeutics reported its cash, cash equivalents, and marketable securities totaled $175.3 million as of March 31, 2026. Research and development expenses for the quarter were $22.1 million, while general and administrative expenses totaled $7.4 million. The company’s net loss for the first quarter was $27.9 million, or $0.62 per share. TScan Therapeutics believes its current cash reserves will fund operations into the second half of 2028. The company is actively advancing its clinical programs, including those focused on blood cancers and solid tumors.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 6, 2026

Author

GOAI